Horizon Industrial Parks IPO
₹57 – ₹57 · Issue Size ₹2,600 CrIPO Overview
Business Model
Our Promoters and Promoter Group", "Restated Consolidated
- We believe the following are our key competitive strengths:
- Largest player with premium-quality offerings strategically located across prime markets, including in-city locations with
- Well positioned to benefit from strong industry tailwinds; Our business is derivative of India’s manufacturing,
- Strong customer relationship - A testament to our ability to lease and actively manage our assets with an ability to provide
- Proven engineering and technical capabilities enabling execution of complex industrial projects;
IPO Timeline
Listing Performance
Risk Factors
Limited (Formerly known as IIFL Securities Limited)
Strengths & Weaknesses
Strengths
- We believe the following are our key competitive strengths:
- Largest player with premium-quality offerings strategically located across prime markets, including in-city locations with
- Well positioned to benefit from strong industry tailwinds; Our business is derivative of India’s manufacturing,
- Strong customer relationship - A testament to our ability to lease and actively manage our assets with an ability to provide
- Proven engineering and technical capabilities enabling execution of complex industrial projects;
Weaknesses
- IIFL Capital Services
Management & Promoters
Pre-IPO Financials
| Period | Revenue (Cr) | PAT (Cr) | Net Worth (Cr) | Total Assets (Cr) |
|---|---|---|---|---|
| April 2022 | ₹3.1 Cr | — | ₹-151.27 Cr | — |
| June 2025 | ₹202.4 Cr | — | ₹0.71 Cr | — |
| March 2025 | ₹3.1 Cr | — | ₹1.66 Cr | — |
| March 2024 | ₹202.3 Cr | — | ₹4.62 Cr | — |
| March 2023 | ₹9.46 Cr | — | ₹3.27 Cr | — |
About
Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medica
Key Regulations and Policies", "History and Certain Corporate Matters", "Our Group Companies", "Restated Consolidated Financial Information", "Proforma Financial Information", "Outstanding Litigation and Material Developments", "Issue Procedure" and
| Exchange | NSE |
| Issue Type | mainboard |
| Sector | According to the JLL Report |
| Face Value | ₹10 per share |
Documents
rupiya.io is for research and education only. IPO data is sourced from public disclosures (DRHP/RHP). Not investment advice. Validate with SEBI-regulated disclosures before acting.